OLMA Insider Trading

Insider Ownership Percentage: 19.40%
Insider Buying (Last 12 Months): $1,728,000.00
Insider Selling (Last 12 Months): $41,931,706.87

Olema Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Olema Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Olema Pharmaceuticals Share Price & Price History

Current Price: $4.42
Price Change: Price Increase of +0.16 (3.76%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for OLMA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$4.42Closing price on 04/20/25:

SEC Filings (Institutional Ownership Changes) for Olema Pharmaceuticals (NASDAQ:OLMA)

91.78% of Olema Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OLMA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$134kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
Olema Pharmaceuticals logo
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Read More on Olema Pharmaceuticals

Today's Range

Now: $4.42
Low: $4.22
High: $4.44

50 Day Range

MA: $4.20
Low: $3.06
High: $5.16

52 Week Range

Now: $4.42
Low: $2.86
High: $16.62

Volume

615,557 shs

Average Volume

856,292 shs

Market Capitalization

$302.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Who are the company insiders with the largest holdings of Olema Pharmaceuticals?

Olema Pharmaceuticals' top insider investors include:
  1. Bain Capital Life Sciences Inv (Major Shareholder)
  2. Biocapital Advisors L Paradigm (Major Shareholder)
  3. Bvf Partners L P/Il (Director)
  4. G Walmsley Graham (Director)
  5. Cyrus Harmon (Director)
  6. David C Myles (Insider)
  7. Sean Bohen (CEO)
  8. Naseem Zojwalla (Insider)
Learn More about top insider investors at Olema Pharmaceuticals.

Who are the major institutional investors of Olema Pharmaceuticals?

Olema Pharmaceuticals' top institutional shareholders include:
  1. Hennion & Walsh Asset Management Inc. — 0.35%
Learn More about top institutional investors of Olema Pharmaceuticals stock.

Which major investors are buying Olema Pharmaceuticals stock?

During the previous quarter, OLMA stock was bought by institutional investors including:
  1. Hennion & Walsh Asset Management Inc.
In the last year, these company insiders have bought Olema Pharmaceuticals stock:
  1. Bain Capital Life Sciences Inv (Major Shareholder)
  2. Biocapital Advisors L Paradigm (Major Shareholder)
  3. Bvf Partners L P/Il (Director)
  4. G Walmsley Graham (Director)
Learn More investors buying Olema Pharmaceuticals stock.